A carregar...
TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
BACKGROUND: Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms. TMPRSS2-ERG fusions have been shown to regulate AR signaling, inter...
Na minha lista:
| Publicado no: | BMC Cancer |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6802314/ https://ncbi.nlm.nih.gov/pubmed/31638934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6185-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|